Stifel Nicolaus is out with its report today on Exelixis EXEL, initiating EXEL at Hold.
In its report, Stifel Nicolaus writes, "We are initiating coverage of Exelixis, Inc. with a Hold rating and $8
current fair value. In our opinion, cabozantinib, Exelixis' lead product, is an active agent for the treatment of prostate cancer and its related bone
complications. However, the degree of this activity, related-adverse event profile, and eventual commercial positioning are yet to be fully characterized. As such, we would wait for further definition of cabozantinib's profile before becoming more positive on Exelixis' shares."
At the time of posting, shares of EXEL were trading at $6.91, up 1.32% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorInitiationAnalyst RatingsHealth CareLife Sciences Tools & ServicesStifel Nicolaus
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in